Stati Uniti - inglese - NLM (National Library of Medicine)

cardinal health 107, llc - magnesium hydroxide (unii: nbz3qy004s) (hydroxide ion - unii:9159uv381p), aluminum hydroxide (unii: 5qb0t2iun0) (aluminum hydroxide - unii:5qb0t2iun0), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - magnesium hydroxide 1200 mg in 30 ml - for the relief of:

Stati Uniti - inglese - NLM (National Library of Medicine)

cardinal health 107, llc - magnesium hydroxide (unii: nbz3qy004s) (hydroxide ion - unii:9159uv381p), aluminum hydroxide (unii: 5qb0t2iun0) (aluminum hydroxide - unii:5qb0t2iun0), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - magnesium hydroxide 2400 mg in 30 ml - as an antacid for symptomatic relief of hyperacidity associated with the diagnosis of peptic ulcer, gastritis, peptic esophagitis, gastric hyperacidity, or hiatal hernia. as an antiflatulent to alleviate the symptoms of gas, including postoperative gas pain.

Stati Uniti - inglese - NLM (National Library of Medicine)

santarus, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (sodium bicarbonate - unii:8mdf5v39qo), magnesium hydroxide (unii: nbz3qy004s) (magnesium hydroxide - unii:nbz3qy004s) - tablet, chewable - 20 mg - zegerid with magnesium hydroxide is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. zegerid with magnesium hydroxide is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. (see clinical pharmacology, clinical studies, gastric ulcer.) zegerid with magnesium hydroxide is indicated for the treatment of heartburn and other symptoms associated with gerd. zegerid with magnesium hydroxide is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. (see clinical pharmacology, clinical studies.) the efficacy of zegerid with magnesium hydroxide used for longer than 8 weeks in these patients has not been established. in the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (eg, hea

Stati Uniti - inglese - NLM (National Library of Medicine)

sato pharmaceutical co., ltd. - magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838), silodrate (unii: 9t3uu8t0qk) (silodrate - unii:9t3uu8t0qk), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - magnesium hydroxide 60 mg - purposes magnesium aluminosilicates    antacid magnesium hydroxide    antacid simethicone    antigas uses relieves these symptoms ■heartburn ■acid indigestion ■sour stomach ■upset stomach and gas associated with these symptoms

Stati Uniti - inglese - NLM (National Library of Medicine)

kroger company - magnesium hydroxide (unii: nbz3qy004s) (hydroxide ion - unii:9159uv381p, magnesium cation - unii:t6v3lhy838) - magnesium hydroxide 1200 mg in 15 ml - saline laxative

Stati Uniti - inglese - NLM (National Library of Medicine)

safecor health, llc - magnesium oxide 400mg (241.3mg elemental magnesium), antacid - relieves: acid indigestion, upset stomach

Stati Uniti - inglese - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - chlordiazepoxide (unii: 6rz6xez3cr) (chlordiazepoxide - unii:6rz6xez3cr), amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - chlordiazepoxide 5 mg - chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. the therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablets occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. chlordiazepoxide and amitriptyline hydrochloride tablets are contraindicated in patients with hypersensitivity to either benzodiazepines or tricyclic antidepressants. it should not be given concomitantly with a monoamine oxidase inhibitor. hyperpyretic crises, severe convulsions and deaths have occurred in patients receiving a tricyclic antidepressant and a monoamine oxidase inhibitor simultaneously. when it is desired to replace a monoamine oxidase inhibitor with chlordiazepoxide and amitriptyline hydrochloride tablets, a minimum of 14 days should be allowed to elapse after the former is discontinued. chlordiazepoxide and amitriptyline hydrochloride tablets should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. this drug is contraindicated during the acute recovery phase following myocardial infarction. chlordiazepoxide and amitriptyline hydrochloride tablets contain chlordiazepoxide, a schedule iv controlled substance. chlordiazepoxide and amitriptyline hydrochloride tablets are a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. abuse and misuse of benzodiazepines may lead to addiction. abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see warnings: abuse, misuse, and addiction). the following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. the following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. death is more often associated with polysubstance use (especially benzodiazepines with other cns depressants such as opioids and alcohol). chlordiazepoxide and amitriptyline hydrochloride tablets may produce physical dependence from continued therapy. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see warnings: dependence and withdrawal reactions). to reduce the risk of withdrawal reactions, use a gradual taper to discontinue chlordiazepoxide and amitriptyline hydrochloride tablets or reduce the dosage (see dosage and administration: discontinuation or dosage reduction of chlordiazepoxide and amitriptyline hydrochloride tablets and warnings: dependence and withdrawal reactions). acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. more severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. protracted withdrawal symptoms may last weeks to more than 12 months. as a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used. tolerance to chlordiazepoxide and amitriptyline hydrochloride tablets may develop from continued therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). tolerance to the therapeutic effect of chlordiazepoxide and amitriptyline hydrochloride tablets may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 10ml ampoules (martindale pharmaceuticals ltd - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - magnesium sulfate dried; sodium hydroxide; magnesium oxide light; chloroform - oral suspension - 47.5mg/1ml ; 15mg/1ml ; 52.5mg/1ml ; .003ml/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - magnesium sulfate dried; sodium hydroxide; magnesium oxide light; chloroform - oral suspension - 47.5mg/1ml ; 15mg/1ml ; 52.5mg/1ml ; .003ml/1ml